Brainlab AG is a German medical technology company headquartered in Munich, specializing in digital medical technologies for surgery and radiation therapy. Founded in 1989 by Stefan Vilsmeier, Brainlab employs approximately 1,979 individuals as of 2025. The company develops software-driven medical technologies designed to digitize, automate, and optimize clinical workflows. Its product offerings include image-guided surgery systems, radiation oncology solutions, digital operating room integration, and medical image exchange platforms. These technologies are utilized in various medical fields, such as neurosurgery, orthopedics, ENT, CMF, spine, and trauma. Brainlab operates as a privately held company, focusing on enhancing the precision and efficiency of medical treatments through innovative solutions aimed at improving patient outcomes. The company has a global presence, with systems installed in around 120 countries, and reported nearly €429.2 million in revenue for the 2022/2023 financial year. Additionally, Brainlab has expanded through acquisitions of companies like medPhoton, Mint Medical, and Level Ex. As of the latest information, there are no indications that Brainlab has filed for or completed an IPO.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
Brainlab AG's offering is currently approved on OTHER. Brainlab AG is headquartered in Germany. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Brainlab AG.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/brainlab" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Brainlab AG — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/brainlab?theme=light as the src instead.
https://www.discoveripo.com/ipo/brainlab/opengraph-image
Brainlab AG IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/brainlab?utm_source=embed&utm_medium=text&utm_campaign=brainlab
Get emailed when Brainlab AG's terms, price, or expected date change — no weekly noise, just this company.
Brainlab AG is listing on OTHER.
Brainlab AG is a German medical technology company headquartered in Munich, specializing in digital medical technologies for surgery and radiation therapy. Founded in 1989 by Stefan Vilsmeier, Brainlab employs approximately 1,979 individuals as of 2025. The company develops software-driven medical technologies designed to digitize, automate, and optimize clinical workflows. Its product offerings include image-guided surgery systems, radiation oncology solutions, digital operating room integration, and medical image exchange platforms. These technologies are utilized in various medical fields, such as neurosurgery, orthopedics, ENT, CMF, spine, and trauma. Brainlab operates as a privately held company, focusing on enhancing the precision and efficiency of medical treatments through innovative solutions aimed at improving patient outcomes. The company has a global presence, with systems installed in around 120 countries, and reported nearly €429.2 million in revenue for the 2022/2023 financial year. Additionally, Brainlab has expanded through acquisitions of companies like medPhoton, Mint Medical, and Level Ex. As of the latest information, there are no indications that Brainlab has filed for or completed an IPO.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy